☆ 4.8 Article

Risk factors and characteristics influencing humoral response to COVID-19 vaccination in patients after allogeneic stem cell transplantation

FRONTIERS IN IMMUNOLOGY (2023)

Related references

Note: Only part of the references are listed.

Article Hematology

SARS-CoV-2-reactive antibody detection after SARS-CoV-2 vaccination in hematopoietic stem cell transplant recipients: Prospective survey from the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group

Jose Luis Pinana et al.

Summary: This multicenter study observed SARS-CoV-2 antibody detection in allogeneic and autologous hematopoietic stem cell transplant recipients post-vaccination, with most recipients showing detectable antibodies. Factors associated with lower antibody detection included lymphopenia, active GvHD, and timing of vaccination in allo-HSCT; and non-Hodgkin's lymphoma and corticosteroid therapy in ASCT recipients. These findings suggest considerations for monitoring SARS-CoV-2 antibodies in immunocompromised patients following stem cell transplants.

AMERICAN JOURNAL OF HEMATOLOGY (2022)

Add to Collection

Article Hematology

Antibody response after 2 and 3 doses of SARS-CoV-2 mRNA vaccine in allogeneic hematopoietic cell transplant recipients

Alexis Maillard et al.

BLOOD (2022)

Add to Collection

Letter Oncology

Robust COVID-19 vaccination response after allogeneic stem cell transplantation using post transplantation cyclophosphamide conditioning

L. M. Morsink et al.

BLOOD CANCER JOURNAL (2022)

Add to Collection

Article Oncology

Two Doses of BNT162b2 mRNA Vaccine in Patients after Hematopoietic Stem Cell Transplantation: Humoral Response and Serological Conversion Predictors

Maciej Majcherek et al.

Summary: Vaccination against SARS-CoV-2 with the BNT162b2 mRNA vaccine is effective and safe in patients after hematopoietic stem cell transplantation, with a high rate of seroconversion. However, the use of calcineurin inhibitors at the time of vaccination has a negative impact on the humoral response.

CANCERS (2022)

Add to Collection

Article Immunology

Humoral Responses and Chronic GVHD Exacerbation after COVID-19 Vaccination Post Allogeneic Stem Cell Transplantation

Caroline Pabst et al.

Summary: This study monitored the antibody response in vaccinated alloSCT patients and found that mRNA-based vaccines can induce strong humoral responses in patients without systemic immunosuppression. However, patients on multiple immunosuppressants rarely developed immunity. The study also identified a correlation between exacerbation of cGVHD, low antibody titres, and elevated levels of angiopoietin-2 (ANG2).

VACCINES (2022)

Add to Collection

Article Hematology

Cellular and humoral immunogenicity of the mRNA-1273 SARS-CoV-2 vaccine in patients with hematologic malignancies

Moraima Jimenez et al.

Summary: Recent studies have shown that patients with hematologic malignancies have a suboptimal humoral response to SARS-CoV-2 mRNA vaccines, while data on cellular immunogenicity are limited. This study aimed to evaluate the humoral and cellular immunogenicity following the second dose of the mRNA-1273 vaccine. The results showed that 76.3% of patients developed humoral immunity and 79% had a cellular response. Factors such as hypogammaglobulinemia, lymphopenia, active hematologic treatment, and anti-CD20 therapy were associated with a poorer humoral response, while age over 65, active disease, lymphopenia, and immunosuppressive treatment for graft-versus-host disease were associated with an impaired cellular response.

BLOOD ADVANCES (2022)

Add to Collection

Letter Surgery

Efficiency of a boost with a third dose of anti-SARS-CoV-2 messenger RNA-based vaccines in solid organ transplant recipients

Arnaud Del Bello et al.

AMERICAN JOURNAL OF TRANSPLANTATION (2022)

Add to Collection

Letter Hematology

Reduced immunogenicity of a third COVID-19 vaccination among recipients of allogeneic hematopoietic stem cell transplantation

Sigrun Einarsdottir et al.

HAEMATOLOGICA (2022)

Add to Collection

Review Oncology

Recommendations for the management of COVID-19 in patients with haematological malignancies or haematopoietic cell transplantation, from the 2021 European Conference on Infections in Leukaemia (ECIL 9)

Simone Cesaro et al.

Summary: SARS-CoV-2 infection can lead to severe outcomes in immunocompromised hematological patients, with high mortality rates observed. Treatment strategies focus on controlling viral replication and inflammation. However, the effectiveness and benefits of preventive and therapeutic measures in hematological patients require further investigation.

LEUKEMIA (2022)

Add to Collection

Review Immunology

Factors Associated With COVID-19 Vaccine Response in Transplant Recipients: A Systematic Review and Meta-analysis

Jiajing Li et al.

Summary: This study aims to assess the humoral response to COVID-19 vaccination in organ transplant and hematopoietic stem cell transplant recipients. The results show that the seroconversion rate is significantly lower in transplant recipients compared to healthy controls, and immunosuppressants are the main risk factors associated with seroconversion failure.

TRANSPLANTATION (2022)

Add to Collection

Review Oncology

Serologic response and safety of COVID-19 vaccination in HSCT or CAR T-cell recipients: a systematic review and meta-analysis

Chenghao Ge et al.

Summary: This meta-analysis revealed a diminished response to COVID-19 vaccines in patients receiving hematopoietic stem cell transplantation (HSCT) or chimeric antigen receptor T cell (CAR T-cell) therapy. These findings can inform regular COVID-19 vaccination at appropriate intervals after HSCT or CAR T-cell therapy.

EXPERIMENTAL HEMATOLOGY & ONCOLOGY (2022)

Add to Collection

Article Virology

Third Early Booster Dose Strategy in France of bnt162b2 SARS-CoV-2 Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients Enhances Neutralizing Antibody Responses

Abdelhakim Ahmed-Belkacem et al.

Summary: Immunocompromised individuals have a weaker immune response after vaccination. Our study showed that HSCT recipients with immunosuppression had increased antibody responses to the Beta and Delta variants after three vaccine doses, but lower response to the Omicron BA.1 variant. Neutralizing antibody levels correlated with anti-S-RBD antibody quantity, indicating it can be used as a reliable marker for humoral immune protection. Additional vaccine doses and preventive measures are recommended for immunocompromised patients in the context of emerging variants.

VIRUSES-BASEL (2022)

Add to Collection

Article Immunology

A Third Dose COVID-19 Vaccination in Allogeneic Hematopoietic Stem Cell Transplantation Patients

Marika Watanabe et al.

Summary: In allogeneic hematopoietic stem cell transplantation patients, a third dose of COVID-19 mRNA vaccine, including BNT162b2 and mRNA-1273, was safe and effective, with majority of patients seroconverting after the third dose without serious adverse events or exacerbation of GVHD.

VACCINES (2022)

Add to Collection

Article Hematology

Safety and Immunogenicity After a Three-Dose SARS-CoV-2 Vaccine Schedule in Allogeneic Stem Cell Transplant Recipients

Muneyoshi Kimura et al.

Summary: In this study, the cell-mediated and humoral immunogenicity of the 3-dose SARS-CoV-2 vaccination schedule in allogeneic stem cell transplant recipients was investigated. The results showed that the third dose of the vaccine was associated with better humoral and cellular immune responses without increasing the risk of graft-versus-host disease (GVHD) or severe adverse effects.

TRANSPLANTATION AND CELLULAR THERAPY (2022)

Add to Collection

Letter Biophysics

Antibody responses to SARS-CoV2 vaccination in allogeneic hematopoietic stem cell transplant recipients

Anne-Claire Mamez et al.

BONE MARROW TRANSPLANTATION (2021)

Add to Collection

Editorial Material Hematology

Antibody response after third BNT162b2 dose in recipients of allogeneic HSCT

Rabah Redjoul et al.

LANCET HAEMATOLOGY (2021)

Add to Collection

Article Hematology

Response to SARS-CoV-2 vaccination in patients after hematopoietic cell transplantation and CAR T-cell therapy

Binod Dhakal et al.

BLOOD (2021)

Add to Collection

Letter Oncology

Antibody response to SARS-CoV-2 vaccines in patients with hematologic malignancies

Lee M. Greenberger et al.

CANCER CELL (2021)

Add to Collection

Letter Medicine, General & Internal

Antibody response after second BNT162b2 dose in allogeneic HSCT recipients

Rabah Redjoul et al.

LANCET (2021)

Add to Collection

Article Hematology

Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study

Kazimieras Maneikis et al.

Summary: Patients with haematological malignancies exhibit blunted and heterogeneous antibody responses after receiving the full course of BNT162b2 mRNA vaccination. Those actively treated with BTKIs, ruxolitinib, venetoclax, or anti-CD20 antibody therapies show the poorest responses, while patients who received tyrosine kinase inhibitors or various types of stem-cell transplantation had higher antibody responses. Severe breakthrough SARS-CoV-2 infections and deaths in fully vaccinated patients with haematological malignancies highlight the importance of continued adherence to non-pharmacological interventions and household vaccination.

LANCET HAEMATOLOGY (2021)

Add to Collection

Article Virology

Evaluation of the EUROIMMUN Anti-SARS-CoV-2 ELISA Assay for detection of IgA and IgG antibodies

Kathleen G. Beavis et al.

JOURNAL OF CLINICAL VIROLOGY (2020)

Add to Collection

Letter Medicine, General & Internal

Shedding of Viable SARS-CoV-2 after Immunosuppressive Therapy for Cancer

Teresa Aydillo et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Medical Laboratory Technology

Comparison of test performance of commercial anti-SARS-CoV-2 immunoassays in serum and plasma samples

Verena Haselmann et al.

CLINICA CHIMICA ACTA (2020)

Add to Collection

Article Hematology

National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report

Madan H. Jagasia et al.

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2015)

Add to Collection

Article Hematology

Defining the Intensity of Conditioning Regimens: Working Definitions

Andrea Bacigalupo et al.

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2009)

Add to Collection

Review Hematology

National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report

AH Filipovich et al.

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2005)

Add to Collection

© Peeref 2019-2024. All rights reserved.